WHO ICTRP trial
Clinical study of PD-1/CTLA-4 bispecial antibody Cadonilimab combined with…
ChiCTR2500102841 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2500102841 |
|---|---|
| Public title | Clinical study of PD-1/CTLA-4 bispecial antibody Cadonilimab combined with chemotherapy in the treatment of inoperable malignant pleural mesothelioma |
| Scientific title | Clinical study of PD-1/CTLA-4 bispecial antibody Cadonilimab combined with chemotherapy in the treatment of inoperable malignant pleural mesothelioma |
| Primary sponsor | West China Hospital of Sichuan University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Malignant pleural mesothelioma |
| Interventions | Experimental group:Cadonilimab 10mg/Kg+ pemetrexed + platinum Or: Cadonilimab 10mg/Kg+ chemotherapy regimen determined by investigator |
| Registration date | May 20, 2025 |
| Target size | Experimental group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: